No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
FBIO Fortress Biotech
- 2.3600
- +0.2100+9.77%
Close Jul 22 16:00 ET
- 2.4000
- +0.0400+1.69%
Post 18:12 ET
48.17MMarket Cap-391P/E (TTM)
2.4150High2.1501Low316.80KVolume2.1700Open2.1500Pre Close727.00KTurnover2.04%Turnover RatioLossP/E (Static)20.41MShares9.000052wk High2.09P/B36.61MFloat Cap1.240052wk Low--Dividend TTM15.51MShs Float190.5000Historical High--Div YieldTTM12.32%Amplitude1.2400Historical Low2.2940Avg Price1Lot Size
Post-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | HC Wainwright & Co. Reiterates Buy on Fortress Biotech, Maintains $24 Price Target
Fortress Biotech Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/19/2024 1000.92% HC Wainwright & Co. $24 → $24 Reiterates Buy → Buy 06/20/2024 — Cantor Fitzgerald
Fortress Biotech's Strategic Financial Moves and Clinical Pipeline Promise Bright Revenue Prospects: Pantginis Issues Buy Rating
Express News | Fortress Biotech's Urica Therapeutics Entered Into An APA Royalty Agreement, Urica Sold The Rights To Its URAT1 Inhibitor Product Candidate In Development For The Treatment Of Gout, Dotinurad, And Related Intellectual Property, Licenses And Agreements...
Express News | Fortress Biotech Inc - Crystalys Issued to Urica Shares of Common Stock Equal to 35% of Crystalys’ Outstanding Equity Under Deal
Express News | Fortress Biotech Inc - Urica Sold Rights to Urat1 Inhibitor Product Candidate to Crystalys
Comments
$Fortress Biotech(FBIO.US$ Fortress Biotech's Urica Therapeutics Entered Into An APA Royalty Agreement, Urica Sold The Rights To Its URAT1 Inhibitor Product Candidate In Development For The Treatment Of Gout, Dotinurad, And Related Intellectual Property, Licenses And Agreements To Crystalys Therapeutics In Return For Common Stock Equal To 35% Of Crystalys' Outstanding Equity
- SEC Filing
- SEC Filing
$Fortress Biotech(FBIO.US$ Reuters· just
Fortress Biotech Inc: FDA Accepted Nda Filing for Dfd-29 to Treat Inflammatory Lesions & Erythema of Rosacea in Adults; Pdufa Goal Date of Nov 4, 2024
Fortress Biotech Inc: FDA Accepted Nda Filing for Dfd-29 to Treat Inflammatory Lesions & Erythema of Rosacea in Adults; Pdufa Goal Date of Nov 4, 2024
2
$Fortress Biotech(FBIO.US$ even after good resilt thus share is going down. holding since last 3 months now.
The low P/S ratio is likely due to investors' concerns about the company's poor revenue performance and underwhelming growth outlook. The company will need a significant change in fortune to justify a higher P/S ratio in the future.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg